ChromaDex and Designs for Health Partner for New Product Development on Niagen®
January 20 2022 - 6:33AM
Business Wire
ChromaDex announces supply agreement with
Designs for Health, offering new Niagen®-formulated products
ChromaDex Corp. (NASDAQ:CDXC) today announced a supply agreement
with Designs for Health, a U.S.-based manufacturer of premium
dietary supplements for healthcare practitioners (HCPs).
ChromaDex’s proprietary healthy aging ingredient Niagen®, the
world’s first and only FDA-safety reviewed and patented form of
nicotinamide riboside, will be added to multi-ingredient Designs
for Health formulas. The new products will be available exclusively
through the company’s extensive healthcare practitioner (HCP)
network.
“We are happy to be working with a science-based company like
Designs for Health to bring Niagen® to healthcare practitioners and
their patients,” said Rob Fried, CEO of ChromaDex. “These
practitioners play a pivotal role in educating consumers on the
importance of NAD+ and providing science-backed health
solutions.”
The Niagen® inclusive formulas will be available to healthcare
practitioners through the Designs for Health network of customers
throughout the United States, Canada, and Australia.
“ChromaDex has been leading the industry with NAD+ research and
we have long admired their approach to creating high quality
products as we believe in developing health products without
compromise to support wellness for all. We are extremely excited to
collaborate with them now and in the future,” said Jonathan
Lizotte, CEO of Designs for Health.
For additional information about ChromaDex, please visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements related to the impact the relationship will
have in bringing Niagen® to healthcare practitioners and their
patients and whether the practitioners will play a pivotal role in
educating consumers on the importance of NAD+ and providing
science-backed health solutions. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects," "anticipates," "intends," "estimates,"
"plans," "potential," "possible," "probable," "believes," "seeks,"
"may," "will," "should," "could" or the negative of such terms or
other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended December 31, 2020,
ChromaDex's Quarterly Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220120005167/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024